# AngioDynamics, Inc. (ANGO) Investor Outlook: Unpacking a 71.55% Potential Upside

- Link: https://www.directorstalkinterviews.com/angiodynamics-inc-ango-investor-outlook-unpacking-a-71-55-potential-upside/4121246908
- Published: 2026-03-27T11:25:57+00:00
- Author: Madison Wilson

AngioDynamics, Inc. (NASDAQ: ANGO), a leader in the healthcare sector specializing
in medical instruments and supplies, is catching the attention of investors with
a noteworthy potential upside of 71.55%, according to analyst ratings. As a company
grounded in innovative medical technology, AngioDynamics designs and manufactures
devices pivotal in treating peripheral vascular diseases and oncology, both in the
U.S. and internationally.

Currently trading at $11.27, AngioDynamics’ stock price sits well within its 52-
week range of $8.40 to $13.64. This stability, coupled with a 50-day moving average
of $10.79 and a 200-day moving average of $10.90, suggests a level of consistency
that might appeal to investors looking for a balance between risk and reward.

Despite the absence of earnings and profitability metrics such as the P/E and PEG
ratios, the company’s forward-looking potential remains strong. Analysts have issued
three buy ratings and set an average target price of $19.33, indicating a substantial
upside potential from its current levels. This bullish sentiment is underpinned 
by the company’s 9% revenue growth, a positive signal in the competitive medical
instruments industry.

However, AngioDynamics is not without challenges. The company reported an earnings
per share (EPS) of -$0.67 and a return on equity (ROE) of -15.26%, which highlights
ongoing struggles with profitability. Yet, the company’s strategic focus on innovative
solutions like the Auryon Atherectomy system and the AlphaVac thrombectomy system
positions it well in the high-demand sectors of vascular and oncology treatment.

Free cash flow of $300,625 further underscores AngioDynamics’ capacity to invest
in growth initiatives despite profitability concerns. The absence of dividend payments
reflects a strategy focused on reinvestment, which can be appealing to growth-oriented
investors.

From a technical perspective, the Relative Strength Index (RSI) of 46.87 indicates
that the stock is neither overbought nor oversold, presenting a neutral stance for
potential investors. The MACD signal of -0.03, slightly above the signal line of-
0.08, suggests cautious optimism, hinting at potential upward momentum.

AngioDynamics’ innovative product lines, including the NanoKnife IRE Ablation System
and the Solero Microwave Tissue Ablation System, are among the cutting-edge solutions
advancing the company’s growth narrative. By focusing on minimally invasive procedures,
AngioDynamics is well-positioned to capitalize on the growing demand for advanced
medical technologies.

For investors seeking an opportunity in the medical devices field, AngioDynamics
offers a compelling case. The significant potential upside, combined with a strong
product portfolio and strategic market positioning, makes ANGO a stock to watch 
closely as it navigates both industry challenges and opportunities for growth.

Share on: